MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced that data from a one-year, Large Simple Safety Study (LSSS) were published online in the CHEST Journal (e-publication ahead of print), the official publication of the American College of Chest Physicians. The objective of the study was to demonstrate that the risk of respiratory death or chronic obstructive pulmonary disease (COPD) exacerbation-related hospitalization for patients treated with BROVANA® (arformoterol tartrate) Inhalation Solution was not greater than 40 percent more than the risk for patients treated with placebo. The trial objective was met demonstrating that COPD patients treated with BROVANA are not at an increased risk of respiratory death or COPD exacerbation-related hospitalizations compared to placebo. The complete study is available on the journal’s website: http://journal.publications.chestnet.org/article.aspx?articleid=1884678.
Help employers find you! Check out all the jobs and post your resume.
